Home Biosimilar Antibodies Immunology & Inflammation CD markers -Interleukins Tibulizumab (Anti-BAFF & IL-17)
For research use only. Not for use in humans.

Tibulizumab (Anti-BAFF & IL-17)

Synonyms: LY3090106

Tibulizumab (LY3090106) is a tetravalent bispecific antibody which potently inhibits both B cell activating factor (BAFF), also known as CD257 and interleukin-17A (IL-17). It is used for the treatment of autoimmune diseases. MW: 201.44 KD.

Tibulizumab (Anti-BAFF & IL-17)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 0
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Tibulizumab (LY3090106) is a tetravalent bispecific antibody which potently inhibits both B cell activating factor (BAFF), also known as CD257 and interleukin-17A (IL-17). It is used for the treatment of autoimmune diseases. MW: 201.44 KD.

Product Details

CAS No. 1849636-24-3
Isotype IgG4-kappa
Source CHO
Storage
(From the date of receipt)		 -80℃(avoid freeze-thaw cycles)

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.